The healthcare community is excited by retatrutide, a innovative dual GIP and GLP-1 receptor that’s showing significant results in preliminary studies . This medication works by replicating natural hormones to affect appetite and promote feelings of fullness , ultimately resulting in noticeable body reduction . While currently under evaluation an